Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center.
Younes NozariAzadeh EshraghiAzita Hajhossein TalasazMostafa BahremandJamshid SalamzadehMojtaba SalarifarHamidreza PourhosseiniArash JalaliSeyedeh Hamideh MortazaviPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2018)
In this study, NAC improved myocardial reperfusion markers and coronary blood flow, as revealed by differences in peak hs-TnT and TIMI flow grade 3 levels, respectively. Further studies with large samples are warranted to elucidate the role of NAC in this population. ClinicalTrials.gov identifier: NCT01741207, and the Iranian Registry of Clinical Trials (IRCT; http://irct.ir ) registration number: IRCT201301048698N8.
Keyphrases
- percutaneous coronary intervention
- blood flow
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- st segment elevation myocardial infarction
- clinical trial
- transcription factor
- left ventricular
- cerebral ischemia
- acute coronary syndrome
- antiplatelet therapy
- coronary artery bypass grafting
- coronary artery
- atrial fibrillation
- heart failure
- phase ii
- coronary artery bypass
- subarachnoid hemorrhage
- case control
- brain injury
- blood brain barrier
- open label
- phase iii
- aortic stenosis
- double blind